China Anesthesia and Respiratory Devices Market Outlook to 2021 - PowerPoint PPT Presentation

Loading...

PPT – China Anesthesia and Respiratory Devices Market Outlook to 2021 PowerPoint presentation | free to download - id: 802388-MDE3Y



Loading


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation
Title:

China Anesthesia and Respiratory Devices Market Outlook to 2021

Description:

Research Beam added a report on “China Anesthesia and Respiratory Devices Market Outlook to 2021” Enquiry about report: – PowerPoint PPT presentation

Number of Views:12

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: China Anesthesia and Respiratory Devices Market Outlook to 2021


1
Non-Small Cell Lung Cancer Therapeutics in Major
Developed Markets to 2021 - Emergence of
Immunotherapies Drives Market Growth and Creates
A Competitive Second-Line
(Type, Mode of action, Crop Type and Geography) -
Size, Share, Global Trends, Company Profiles,
Demand, Insights, Analysis, Research, Report,
Opportunities, Segmentation and Forecast, 2013 -
2020
TELEPHONE 1 (503) 894-6022 E-MAIL
sales_at_researchbeam.com
Published on Oct 2014
2


Report Overview
  • Summary
  • Non-Small Cell Lung Cancer (NSCLC) is the second
    most common cancer globally, and the most common
    cause of cancer-related mortality. Such a poor
    outlook, particularly for patients with advanced
    disease, has created a pressing need for improved
    therapeutic options. The NSCLC market is
    undergoing a gradual change from a focus on
    generic chemotherapy regimens to complex
    treatment landscape based on different NSCLC
    subtypes and the presence of various molecular
    aberrations. In the current market, patients with
    non-squamous histology can be treated with more
    efficacious therapies such as Alimta
    (pemetrexed), while patients harboring activating
    mutations in EGFR or ALK can be prescribed
    targeted therapy. While the NSCLC developmental
    pipeline must aim to improve the outlook for all
    patients, there is currently a lack of options
    for patients with squamous cell histology or
    other detectable molecular characteristics
    besides EFGR and ALK mutations.
  • Read More At http//www.researchbeam.com/non-smal
    l-cell-lung-cancer-therapeutics-in-major-developed
    -to-2021-emergence-of-immunotherapies-drives-growt
    h-and-creates-a-competitive-second-line-market

3


Table of Content
1 Table of Contents 5 1.1 List of Tables 6 1.2
List of Figures 7 2 Introduction 8 2.1 Disease
Introduction 8 2.2 Epidemiology 9 3 Marketed
Products 29 3.1 Overview 29 3.2 Chemotherapies
29 4 NSCLC Pipeline 40 4.1 Overview 40 4.2
Mechanisms of Action and Targets in the Pipeline
43
4


Table of Content
5 Market Forecast 81 5.1 Geographical Markets
81 5.2 Drivers and Barriers 93 6 Strategic
Consolidations 95 6.1 Major Licensing Deals
95 6.2 Major Co-Development Deals 99 7 Appendix
104 7.1 References 104 7.2 Abbreviations
108 Enquire At http//www.researchbeam.com/no
n-small-cell-lung-cancer-therapeutics-in-major-dev
eloped-to-2021-emergence-of-immunotherapies-drives
-growth-and-creates-a-competitive-second-line-mark
et/enquire-about-report
5



FOR MORE DETAILS
Visit us at
http//www.researchbeam.com/non-small-cell-lung-ca
ncer-therapeutics-in-major-developed-to-2021-emerg
ence-of-immunotherapies-drives-growth-and-creates-
a-competitive-second-line-market
Stay With Us
5933 NE Win Sivers Drive, 205, Portland, OR
97220 United States
TELEPHONE 1 (800) 910-6452 DIRECT 1 (503)
894-6022 E-MAIL sales_at_researchbeam.com
About PowerShow.com